Investors
EastGate Biotech Unveils Manufacturing Plans in an MOU with Mystic Pharmaceuticals Limited for its Liquid Insulin Mouth Rinse Solution
June 21, 2018
Focus on the manufacturing of the company’s liquid insulin mouth rinse solution for specific markets. Presently, EastGate is developing its insulin mouth rinse in the Philippines, Pakistan, and Europe through its JV with Nico Innovapharma.
Read moreMorphs into Global Licensing Play with $36 Million in Milestone Payments
June 20, 2018
Morphs into Global Licensing
Read moreEastGate Biotech Strikes Investment and Licensing Collaboration with Nico Innovapharma for Liquid Insulin Mouth Rinse Solution for the European Market
June 20, 2018
EastGate Biotech Strikes Investment and Licensing Collaboration with Nico Innovapharma for Liquid Insulin Mouth Rinse Solution for the European Market
Read moreEastGate Biotech Enters into a Financial Agreement
May 2, 2018
WEST CALDWELL, NJ and TORONTO, May 2, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced that it had entered into a Financial Loan Agreement with a high net worth individual on April 20, 201
Read moreEastGate Biotech Announces Joint Venture with Netris/Origin Biopharmaceuticals for Pakistani Market
April 17, 2018
WEST CALDWELL, NJ and TORONTO, April 17, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced a joint venture agreement with Netris /Origin Biopharmaceuticals (Netris/Origin) to conduct clinical trials, register, and commercialize the Netris/Origin pipeline for the Pakistani market.
Read moreEastGate Biotech Announces Definitive Agreement with Genluiching Mining Corporation.
April 11, 2018
WEST CALDWELL, NJ and TORONTO, April 10, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced a definitive agreement with Genluiching Mining Corporation. As per the previously announced Memorandum of Understanding Genluiching Mining will investment up to $5 million USD in tranches. The first tranche will be expected sometime in May.
Read moreEastGate Biotech Corp., CEO Anna Gluskin and President, Rose Perri Visit Uptick Newswire’s “Stock Day” with Everett Jolly
March 30, 2018
EastGate Biotech Corp., CEO Anna Gluskin and President, Rose Perri Visit Uptick Newswire’s “Stock Day” with Everett Jolly
Read moreEastGate Biotech Announces that it has reached a Definitive Settlement Agreement with Northbridge Financial Inc..
March 23, 2018
EastGate Biotech Announces that it has reached a Definitive Settlement Agreement with Northbridge Financial Inc.. The Share Reserve with Transfer Agent has been cancelled and all remaining shares have been returned to EastGate Biotech. WEST CALDWELL, NJ and TORONTO, March 22, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced today that it has reached a definitive settlement agreement with Northbridge Financial. Last year EastGate entered into a series of 3(a)(10) exemptions with Northbridge Financial detailed in 2 Form 8-K filings. Northbridge Financial released all remaining debt from the Settlement Agreement dated May 9, 2017 between Northbridge Financial Inc. and EastGate Biotech Corp.. As a result NorthBridge Financial has released all remaining shares in the reserve with the EastGate’s Transfer Agent back to the company.
Read moreEASTGATE BIOTECH ENTERS INTO A MOU WITH GENLUICHING MINING CORP. & AAH & INTERNATIONAL ASSOCIATES INC. OF THE PHILIPPINES
March 13, 2018
WEST CALDWELL, NJ and TORONTO, March 13, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, is pleased to announce that has signed a Memorandum of Understanding (MOU) with Genluiching Mining Corporation (Genluiching) and AAH & International Associates (AAH), Incorporated. Within the scope of the MOU, both parties, located in the Philippines, intend to invest between PHP 100,000,000 – PHP 300,000,000 (approximately $2 million USD to $5.8 million USD) either in full or in tranches. Similar to the recently announce BuPharco Joint Venture, Genluiching and AAH will pay for all expenses related to financing as well as the clinical trials, however ETBI is expected to be the lead manager of the JV.
Read moreEASTGATE BIOTECH ANNOUNCES LICENSING/DISTRIBUTION MOU WITH BUPHARCO FOR THE INSULIN MOUTH RINSE IN THE PHILIPPINES FOR TYPE 2 DIABETES PATIENTS
March 6, 2018
ST CALDWELL, NJ and TORONTO, March 5, 2018 (AccessNewswire-) EastGate Biotech Corp. (PinkSheets: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes. We are thrilled to announce today that EastGate has signed a Memorandum of Understanding (MOU) with Bukidnon Pharmaceutical Multi-Purpose Cooperatives (BuPharco). The MOU outlines the strategic plan to commercialize the oral insulin mouth rinse delivered through the buccal mucosa (inner lining of mouth) and penetrates the blood brain barrier. BuPharco will initially compile, submit, and file all dossiers to the FDA of the Philippines with the full support of EastGate’s team assisting in the compilation of the master drug file.
Read more